Statistics

Total Visits

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer54

Select a period of time:

Number of views in the range

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer12

Views

Views
September 20255
October 20251
November 20252
December 20252
January 20261
February 20260
March 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
United Kingdom3
Argentina2
Brazil1
Colombia1
Ecuador1
South Africa1
 

Top cities views

Views
Cape Town1
City of Westminster1
Córdoba1
Dallas1
Florida1
Manta1
Medellín1
Niterói1